Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015 (2015), Article ID 854307, 10 pages
http://dx.doi.org/10.1155/2015/854307
Review Article

Review on the Applications and Molecular Mechanisms of Xihuang Pill in Tumor Treatment

1Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medicine Sciences, No. 5 Beixiange, Xicheng District, Beijing 100053, China
2Beijing University of Chinese Medicine, No. 11 North Third Ring Road East, Chaoyang District, Beijing 100029, China
3Beijing Tongren Hospital, Capital Medical University, No. 2, Chongwenmennei Street, Dongcheng District, Beijing 100730, China
4Institute of Medical Information, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 3 Yabao Road, Chaoyang District, Beijing 100020, China

Received 29 January 2015; Revised 16 May 2015; Accepted 21 May 2015

Academic Editor: Olumayokun A. Olajide

Copyright © 2015 Qiujun Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Li and H.-S. Lin, “Integrative medicine: a characteristic china model for cancer treatment,” Chinese Journal of Integrative Medicine, vol. 17, no. 4, pp. 243–245, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Li, L. Li, R. Liu, and H.-S. Lin, “Establishing Chinese medicine characteristic tumor response evaluation system is the key to promote internationalization of Chinese medicine oncology,” Chinese Journal of Integrative Medicine, vol. 18, no. 10, pp. 730–736, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. B. H. Zhang, S. Q. Gao, and D. X. Fu, “17 side-effect cases analysis of XH,” China Journal of Chinese Materia Medica, vol. 34, no. 2, pp. 234–235, 2009. View at Google Scholar
  4. N. Niitsu, “Current treatment strategy of diffuse large B-cell lymphomas,” International Journal of Hematology, vol. 92, no. 2, pp. 231–237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Oliver, C. Guillermo, P. Martínez, and L. Díaz, “Comparison between CHOP-like and R-CHOP in diffuse large B cell and follicular lymphoma,” Revista Medica de Chile, vol. 141, no. 7, pp. 844–852, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Y. Wang, H. F. Li, Q. Zu, H. G. Xiao, and Y. Y. Dang, “Clinical research of Xihuang Pill on 60 NHL cases treatment combined with CHOP regimen chemotherapy,” Journal of Shandong University of Traditional Chinese Medicine, vol. 36, no. 4, pp. 313–315, 2012. View at Google Scholar
  7. C. Desantis, J. Ma, L. Bryan, and A. Jemal, “Breast cancer statistics, 2013,” CA Cancer Journal for Clinicians, vol. 64, no. 1, pp. 52–62, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. X. Chen, G. Ye, C. Zhang et al., “Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer,” Breast Cancer Research and Treatment, vol. 142, no. 3, pp. 549–558, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Ando, H. Yamauchi, K. Aogi et al., “Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression,” Breast Cancer Research and Treatment, vol. 145, no. 2, pp. 401–409, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. M. J. Chung, G. J. Lee, Y. J. Suh et al., “Setup error and effectiveness of weekly image-guided radiation therapy of tomodirect for early breast cancer,” Cancer Research and Treatment, 2015. View at Publisher · View at Google Scholar
  11. S. M. Swain, J. Baselga, S. B. Kim et al., “Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer,” The New England Journal of Medicine, vol. 372, no. 8, pp. 724–734, 2015. View at Publisher · View at Google Scholar
  12. M. K. Barton, “Bevacizumab in neoadjuvant chemotherapy increases the pathological complete response rate in patients with triple-negative breast cancer,” CA: A Cancer Journal for Clinicians, vol. 64, no. 3, pp. 155–156, 2014. View at Publisher · View at Google Scholar
  13. W. D. Figg, K. Cook, and R. Clarke, “Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer,” Cancer Biology & Therapy, vol. 15, no. 12, pp. 1586–1587, 2014. View at Publisher · View at Google Scholar
  14. R. Hong, Y. Q. Wu, and Y. Wu, “Effects of xihuangwan in assistant treatment of patients with advanced breast cancer,” Zhongguo Zhong Yao Za Zhi, vol. 39, no. 6, pp. 1120–1123, 2014. View at Google Scholar
  15. J. Jin and Z. H. Li, “Integrated Xihuang Pill and chemotherapy in treating 30 patients with breast cancer,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 25, no. 5, pp. 715–716, 2010. View at Google Scholar
  16. W. J. Jia, F. Tian, and X. L. Xing, “Treating breast cancer with bone metastasis using combined Xihuangwan and zoledronic acid injection,” World Science and Technology (Modernization of Traditional Chinese Medicine and Materia Medica), vol. 3, no. 11, pp. 450–453, 2009. View at Google Scholar
  17. Y. M. Shen, “West Yellow Pill combined western medicine treatment of breast cancer and parallel controlled study,” Journal of Practical Traditional Chinese Internal Medicine, vol. 28, no. 3, pp. 127–128, 2014. View at Google Scholar
  18. B. Liu, S. Yu, L. Xing, X. D. Zhao, Y. Q. Lv, and Q. Z. Gaq, “Analysis of therapeutical effects of Xihuang Pills with intraarterial intervention chemotherapy on 80 cases of advanced primary hepatic carcinoma,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 25, no. 6, pp. 947–948, 2010. View at Google Scholar
  19. Z. Q. Cheng, “Clinical observation on Xihuang Pill in treating 23 cases of advanced primary hepatic cancer,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 25, no. 1, pp. 52–54, 2010. View at Google Scholar
  20. Z. J. Zhang, “Clinical observation on Xihuang Pill in treating 28 cases of advanced primary hepatic cancer,” Hebei Journal of Traditional Chinese Medicine, vol. 34, no. 4, pp. 581–582, 2012. View at Google Scholar
  21. X. P. Fu and M. F. Zhong, “Effect analysis on Xihuang Pill in advanced stage gastric cancer treatment combined with chemotherapy,” Contemporary Medicine, vol. 20, no. 23, pp. 156–157, 2014. View at Google Scholar
  22. Z. Q. Cheng and W. T. Zhu, “Clinical observation on Xihuang Pill combined with chemotherapy in treating 18 cases of advanced esophageal cancer,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 25, no. 8, pp. 1302–1304, 2010. View at Google Scholar
  23. Y. P. Fan, “1 case of brain stem glioma treated by syndrome differentiation of TCM and Xihuangwan,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 25, no. 2, pp. 245–248, 2010. View at Google Scholar
  24. J. J. Ren and Q. W. Wang, “Clinical observations of Xihuang Pil on treating radiation-induced oral mucositis combined with Kangfuxin solution,” Chinese Remedies and Clinics, vol. 14, no. 2, pp. 255–257, 2014. View at Google Scholar
  25. Z. J. Jia and Y. Chen, “1 case report of Xihuang Pill on treating chemotherapy-induced phlebitis,” Xinjiang Journal of Traditional Chinese Medicine, vol. 28, no. 5, pp. 93–94, 2010. View at Google Scholar
  26. S. Björner, P. A. Fitzpatrick, Y. Li et al., “Epithelial and stromal microRNA signatures of columnar cell hyperplasia linking Let-7c to precancerous and cancerous breast cancer cell proliferation,” PLoS ONE, vol. 9, no. 8, 2014. View at Publisher · View at Google Scholar
  27. Y. B. Sui, “Clinical study of Xihuang Pills in treating cyclomastopathy,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 25, no. 4, pp. 618–619, 2010. View at Google Scholar
  28. T. Tu, M. A. Budzinska, A. E. Maczurek et al., “Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development,” International Journal of Molecular Sciences, vol. 15, no. 6, pp. 9422–9458, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Qian, M. Wei, H. Qiu et al., “A scoring system for prediction of early recurrence after liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma,” Chinese Medical Journal, vol. 127, no. 24, pp. 4171–4176, 2014. View at Google Scholar
  30. J. Klein, R. Korol, S. S. Lo et al., “Stereotactic body radiotherapy: an effective local treatment modality for hepatocellular carcinoma,” Future Oncology, vol. 10, no. 14, pp. 2227–2241, 2014. View at Publisher · View at Google Scholar
  31. M. Peck-Radosavljevic, “Drug therapy for advanced-stage liver cancer,” Liver Cancer, vol. 3, no. 2, pp. 125–131, 2014. View at Publisher · View at Google Scholar
  32. H. J. Prajapati, M. Xing, S. I. Spivey Hanish Jr. et al., “Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC,” The American Journal of Roentgenology, vol. 203, no. 6, pp. W706–W714, 2014. View at Google Scholar
  33. H. Nishikawa, Y. Osaki, R. Kita et al., “Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma,” Oncology Reports, vol. 31, no. 1, pp. 65–72, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA: Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Giuliani, M. Miccini, and L. Basso, “Extent of lymphadenectomy and perioperative therapies: two open issues in gastric cancer,” World Journal of Gastroenterology, vol. 20, no. 14, pp. 3889–3904, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Y. Park, L. von Karsa, and R. Herrero, “Prevention strategies for gastric cancer: a global perspective,” Clinical Endoscopy, vol. 47, no. 6, pp. 478–489, 2014. View at Publisher · View at Google Scholar
  37. L. Shen, Y.-S. Shan, H.-M. Hu et al., “Management of gastric cancer in Asia: resource-stratified guidelines,” The Lancet Oncology, vol. 14, no. 12, pp. e535–e547, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. X. Pang, W. Wei, W. Leng et al., “Radiotherapy for gastric cancer: a systematic review and meta-analysis,” Tumor Biology, vol. 35, no. 1, pp. 387–396, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Saito, Y. Kurokawa, S. Takiguchi, M. Mori, and Y. Doki, “Current status of function-preserving surgery for gastric cancer,” World Journal of Gastroenterology, vol. 20, no. 46, pp. 17297–17304, 2014. View at Publisher · View at Google Scholar
  40. T. Gotoda, C. Kusano, and F. Moriyasu, “Future perspective of gastric cancer endotherapy,” Annals of Translational Medicine, vol. 2, no. 3, article 25, 2014. View at Google Scholar
  41. C. Gomez-Martín, F. Lopez-Rios, J. Aparicio et al., “A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond,” Cancer Letters, vol. 351, no. 1, pp. 30–40, 2014. View at Publisher · View at Google Scholar
  42. M. Orditura, G. Galizia, V. Sforza et al., “Treatment of gastric cancer,” World Journal of Gastroenterology, vol. 20, no. 7, pp. 1635–1649, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. I. Roato, “Bone metastases: when and how lung cancer interacts with bone,” World Journal of Clinical Oncology, vol. 5, no. 2, pp. 149–155, 2014. View at Publisher · View at Google Scholar
  44. A. V. Taubenberger, “In vitro microenvironments to study breast cancer bone colonisation,” Advanced Drug Delivery Reviews, vol. 79-80, pp. 135–144, 2014. View at Publisher · View at Google Scholar
  45. B. Hua, Y. Gao, X. Kong, L. Yang, W. Hou, and Y. Bao, “New insights of nociceptor sensitization in bone cancer pain,” Expert Opinion on Therapeutic Targets, vol. 19, no. 2, pp. 227–243, 2015. View at Publisher · View at Google Scholar
  46. K. Cetin, C. F. Christiansen, J. B. Jacobsen, M. Nørgaard, and H. T. Sørensen, “Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study,” Lung Cancer, vol. 86, no. 2, pp. 247–254, 2014. View at Publisher · View at Google Scholar
  47. C. Rolfo, L. E. Raez, A. Russo et al., “Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor,” Expert Opinion on Biological Therapy, vol. 14, no. 1, pp. 15–26, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. B. Yanju, L. Yang, B. Hua et al., “A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain,” Supportive Care in Cancer, vol. 22, no. 3, pp. 825–836, 2014. View at Publisher · View at Google Scholar
  49. Y. Bao, X. Kong, L. Yang et al., “Complementary and alternative medicine for cancer pain: an overview of systematic reviews,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 170396, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. S. B. Park, D. Goldstein, A. V. Krishnan et al., “Chemotherapy-induced peripheral neurotoxicity: a critical analysis,” CA: Cancer Journal for Clinicians, vol. 63, no. 6, pp. 419–437, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. L. Saleh-Ebrahimi, F. Zwicker, M. W. Muenter et al., “Intensity modulated radiotherapy (IMRT) combined with concurrent but not adjuvant chemotherapy in primary nasopharyngeal cancer—a retrospective single center analysis,” Radiation Oncology, vol. 8, no. 1, article 20, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. S. D. Baxter, W. A. Teft, Y.-H. Choi, E. Winquist, and R. B. Kim, “Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A422,” Breast Cancer Research and Treatment, vol. 145, no. 2, pp. 419–428, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. J. L. Andersen and S. Kornbluth, “The tangled circuitry of metabolism and apoptosis,” Molecular Cell, vol. 49, no. 3, pp. 399–410, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. L. Chen, Y. Luo, T. Liu et al., “Label-free electrochemical immunoassay of Bcl-2 protein expression on tumor cells,” Talanta, vol. 132, pp. 479–485, 2015. View at Publisher · View at Google Scholar
  56. M. Hassan, H. Watari, A. AbuAlmaaty, Y. Ohba, and N. Sakuragi, “Apoptosis and molecular targeting therapy in cancer,” BioMed Research International, vol. 2014, Article ID 150845, 23 pages, 2014. View at Publisher · View at Google Scholar
  57. P. Huang, B. Ye, Y. Yang, J. Shi, and H. Zhao, “MicroRNA-181 functions as a tumor suppressor in non-small cell lung cancer (NSCLC) by targeting Bcl-2,” Tumour Biology, vol. 36, no. 5, pp. 3381–3387, 2015. View at Publisher · View at Google Scholar
  58. H. Xu, L. R. Cui, and J. C. Liu, “Study on the effects of Xihuang Pill on the expression of Bcl-2 mRNA of mice bearing H22,” Modern Preventive Medicine, vol. 38, no. 11, pp. 2120–2121, 2011. View at Google Scholar
  59. L. F. Li, R. S. Chen, X. M. Liu, Q. W. Jin, and X. G. Deng, “Mechanism of Xihuang Pill on inducing liver cancer cell apoptosis,” Chinese Archives of Traditional Chinese Medicine, vol. 22, no. 1, pp. 125–126, 2004. View at Google Scholar
  60. J. R. Shen, B. D. Zhu, X. H. Qin, and X. S. Zhang, “Antitumous effects of Xi Huang Pellet on diverse human malignant tumor cell strains (MDA-MB-231, SMMC7721, T24, HL-60, A549),” Journal of Sichuan Traditional Chinese Medicine, vol. 24, no. 10, pp. 10–13, 2006. View at Google Scholar
  61. M. Wang, J.-Y. Meng, and S.-F. He, “Xihuang Pill induces mesenchymal-epithelial transition and inhibits loss of apical-basal polarity in colorectal cancer cell through regulating ZEB1-SCRIB loop,” Chinese Journal of Integrative Medicine, vol. 20, no. 10, pp. 751–757, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. K. Steinestel, S. Eder, A. Schrader, and J. Steinestel, “Clinical significance of epithelial-mesenchymal transition,” Clinical and Translational Medicine, vol. 3, no. 1, article 17, 2014. View at Publisher · View at Google Scholar
  63. X. Lin, Z. Yi, J. Diao et al., “ShaoYao decoction ameliorates colitis-associated colorectal cancer by downregulating proinflammatory cytokines and promoting epithelial-mesenchymal transition,” Journal of Translational Medicine, vol. 12, no. 1, article 105, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. A. K. Chaudhary, S. Pandya, K. Ghosh, and A. Nadkarni, “Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview,” Mutation Research, vol. 753, no. 1, pp. 7–23, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. L. N. Sun, J. Y. Meng, W. Wang et al., “Effect of Xihuang Pills on protein expressions of MMP-2 and MMP-9 in human colorectal carcinoma LoVo cell,” Tianjin Journal of Traditional Chinese Medicine, vol. 29, no. 4, pp. 378–380, 2012. View at Google Scholar
  66. Y. Y. Wang, Y. Z. Ren, Z. Jiao, C. Q. Zeng, W. B. Gao, and W. B. Liang, “The influence of Xihuang Pill on the formation of con tumor-bearing mice,” Pharmacology and Clinics of Chinese Materia Medica, vol. 30, no. 4, pp. 11–13, 2014. View at Google Scholar
  67. F. Z. Shahneh, B. Baradaran, F. Zamani, and L. Aghebati-Maleki, “Tumor angiogenesis and anti-angiogenic therapies,” Human Antibodies, vol. 22, no. 1-2, pp. 15–19, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. Y. Matsuda, M. Hagio, and T. Ishiwata, “Nestin: a novel angiogenesis marker and possible target for tumor angiogenesis,” World Journal of Gastroenterology, vol. 19, no. 1, pp. 42–48, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. F. Loupakis, C. Cremolini, G. Masi et al., “Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 371, no. 17, pp. 1609–1618, 2014. View at Publisher · View at Google Scholar
  70. G. Giordano, A. Febbraro, M. Venditti et al., “Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept,” Gastroenterology Research and Practice, vol. 2014, Article ID 526178, 13 pages, 2014. View at Publisher · View at Google Scholar
  71. S. F. Wang, K. C. Liu, X. M. Wang et al., “Effect of Xihuang Pill on angiogenesis in Zebrafish embryo,” Chinese Journal of Hospital Pharmacy, vol. 30, no. 10, pp. 821–823, 2010. View at Google Scholar
  72. A. Zeuner, M. Todaro, G. Stassi, and R. De Maria, “Colorectal cancer stem cells: from the crypt to the clinic,” Cell Stem Cell, vol. 15, no. 6, pp. 692–705, 2014. View at Publisher · View at Google Scholar
  73. S. Dawood, L. Austin, and M. Cristofanilli, “Cancer stem cells: implications for cancer therapy,” Oncology, vol. 28, no. 12, pp. 1101–1107, 2014. View at Google Scholar
  74. F. Pistollato, F. Giampieri, and M. Battino, “The use of plant-derived bioactive compounds to target cancer stem cells and modulate tumor microenvironment,” Food and Chemical Toxicology, vol. 75, pp. 58–70, 2015. View at Publisher · View at Google Scholar
  75. H. Xiao, X. H. Qin, Y. Lai, J. R. Shen, and L. Lai, “Containing Xihuang Pill drug serum regulates growth of lung cancer stem cells by controlling cyclin D1 of Wnt signaling pathway,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 20, no. 15, pp. 172–176, 2014. View at Google Scholar
  76. W. H. Fridman, R. Remark, J. Goc et al., “The immune microenvironment: a major player in human cancers,” International Archives of Allergy and Immunology, vol. 164, no. 1, pp. 13–26, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. Q. J. Guo, J. Li, and H. S. Lin, “Effect and molecular mechanisms of traditional Chinese medicine on regulating tumor immunosuppressive microenvironment,” BioMed Research International. In press.
  78. A. da Cunha, M. A. Michelin, and E. F. Murta, “Pattern response of dendritic cells in the tumor microenvironment and breast cancer,” World Journal of Clinical Oncology, vol. 5, no. 3, pp. 495–502, 2014. View at Publisher · View at Google Scholar
  79. A. Makkouk and G. J. Weiner, “Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge,” Cancer Research, vol. 75, no. 1, pp. 5–10, 2015. View at Publisher · View at Google Scholar
  80. J. Ma, S. Guan, W. Yang et al., “Experimental study on the effect of Xihuang Pill ethanol extract on immune function of tumor-bearing rats,” Pharmacology and Clinics of Chinese Materia Medica, vol. 29, no. 4, pp. 124–126, 2013. View at Google Scholar
  81. S. Guan, W. Yang, J. X. Hu, J. Ma, W. B. Gao, and W. B. Liang, “Effect of chloroform extract of Xihuang Pill on the immune clearance function of tumor-bearing rats,” Chinese Journal of Modern Applied Pharmacy, vol. 31, no. 2, pp. 144–148, 2014. View at Google Scholar
  82. W. Yang, S. Guan, J. X. Hu et al., “Experimental study on antitumor effect of volatile oil of Xihuang Pill and its immune mechanism,” World Science and Technology—Modernization of Traditional Chinese Medicine, vol. 16, no. 1, pp. 68–72, 2014. View at Google Scholar
  83. A. Moussaieff and R. Mechoulam, “Boswellia resin: from religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials,” Journal of Pharmacy and Pharmacology, vol. 61, no. 10, pp. 1281–1293, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Alam, H. Khan, L. Samiullah, and K. M. Siddique, “A review on phytochemical and pharmacological studies of Kundur (Boswellia serrata roxb ex colebr.)—a Unani drug,” Journal of Applied Pharmaceutical Science, vol. 2, no. 3, pp. 148–156, 2012. View at Google Scholar · View at Scopus
  85. A. C. Estrada, T. Syrovets, K. Pitterle et al., “Tirucallic acids are novel pleckstrin homology domain-dependent akt inhibitors inducing apoptosis in prostate cancer cells,” Molecular Pharmacology, vol. 77, no. 3, pp. 378–387, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Liu, Q. Wu, P. Chen et al., “A boswellic acid-containing extract ameliorates schistosomiasis liver granuloma and fibrosis through regulating NF-κB signaling in mice,” PLoS ONE, vol. 9, no. 6, Article ID e100129, 2014. View at Publisher · View at Google Scholar
  87. S. Shishodia, K. B. Harikumar, S. Dass, K. G. Ramawat, and B. B. Aggarwal, “The guggul for chronic diseases: ancient medicine, modern targets,” Anticancer Research, vol. 28, no. 6, pp. 3647–3664, 2008. View at Google Scholar · View at Scopus
  88. E. Amiel, R. Ofir, N. Dudai, E. Soloway, T. Rabinsky, and S. Rachmilevitch, “β-Caryophyllene, a compound isolated from the biblical balm of gilead (Commiphora gileadensis), is a selective apoptosis inducer for tumor cell lines,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 872394, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. T. Shen, G.-H. Li, X.-N. Wang, and H.-X. Lou, “The genus Commiphora: a review of its traditional uses, phytochemistry and pharmacology,” Journal of Ethnopharmacology, vol. 142, no. 2, pp. 319–330, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Sarfaraz, I. A. Siddiqui, D. N. Syed, F. Afaq, and H. Mukhtar, “Guggulsterone modulates MAPK and NF-κB pathways and inhibits skin tumorigenesis in SENCAR mice,” Carcinogenesis, vol. 29, no. 10, pp. 2011–2018, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. D. Xiao and S. V. Singh, “z-Guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, inhibits angiogenesis in vitro and in vivo,” Molecular Cancer Therapeutics, vol. 7, no. 1, pp. 171–180, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. H. B. Xu, Z. L. Shen, J. Fu, and L. Z. Xu, “Reversal of doxorubicin resistance by guggulsterone of Commiphora mukul in vivo,” Phytomedicine, vol. 21, no. 11, pp. 1221–1229, 2014. View at Publisher · View at Google Scholar
  93. H. Zhen, Y. Zhang, Z. Fang, Z. Huang, C. You, and P. Shi, “Toona sinensis and Moschus decoction induced cell cycle arrest in human cervical carcinoma HeLa cells,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 121276, 8 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  94. Y. Meng, Q. Xiao, J. Bai et al., “Resolution and chiral recognition of muscone as well as actions on neural system,” Journal of Asian Natural Products Research, vol. 16, no. 12, pp. 1166–1170, 2014. View at Publisher · View at Google Scholar
  95. Z. Chen, X. Gong, Y. Lu et al., “Enhancing effect of borneol and muscone on geniposide transport across the human nasal epithelial cell monolayer,” PLoS ONE, vol. 9, no. 7, Article ID e101414, 2014. View at Publisher · View at Google Scholar
  96. W. Kong, J. Wang, Q. Zang et al., “Fingerprint-efficacy study of artificial Calculus bovis in quality control of Chinese materia medica,” Food Chemistry, vol. 127, no. 3, pp. 1342–1347, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. N. S. Horowitz, J. Hua, M. A. Powell, R. K. Gibb, D. G. Mutch, and T. J. Herzog, “Novel cytotoxic agents from an unexpected source: bile acids and ovarian tumor apoptosis,” Gynecologic Oncology, vol. 107, no. 2, pp. 344–349, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. Y. Huang, S. Chen, J. Cui et al., “Synthesis and cytotoxicity of A-homo-lactam derivatives of cholic acid and 7-deoxycholic acid,” Steroids, vol. 76, no. 7, pp. 690–694, 2011. View at Publisher · View at Google Scholar · View at Scopus
  99. J. A. Siddiqui, A. Singh, M. Chagtoo, N. Singh, M. M. Godbole, and B. Chakravarti, “Phytochemicals for breast cancer therapy: current status and future implications,” Current Cancer Drug Targets, vol. 15, no. 2, pp. 116–135, 2015. View at Google Scholar
  100. D. A. Fuchs and R. K. Johnson, “Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison,” Cancer Treatment Reports, vol. 62, no. 8, pp. 1219–1222, 1978. View at Google Scholar · View at Scopus
  101. W. Bochu, Z. Liancai, and C. Qi, “Primary study on the application of Serum Pharmacology in Chinese traditional medicine,” Colloids and Surfaces B: Biointerfaces, vol. 43, no. 3-4, pp. 194–197, 2005. View at Publisher · View at Google Scholar · View at Scopus
  102. B. Cao, Y. Qi, Y. Yang et al., “20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer,” PLoS ONE, vol. 9, no. 11, Article ID e111201, 2014. View at Publisher · View at Google Scholar
  103. X. Kou, X. Liu, Q. Yang et al., “Kanglaite injection combined with chemotherapy versus chemotherapy alone in the treatment of advanced non-small cell lung carcinoma,” Journal of Cancer Research and Therapeutics, vol. 10, no. 5, pp. 46–51, 2014. View at Publisher · View at Google Scholar
  104. X. Lei, J. Chen, C. Liu, J. Lin, J. Lou, and H. Shang, “Status and thoughts of Chinese patent medicines seeking approval in the US market,” Chinese Journal of Integrative Medicine, vol. 20, no. 6, pp. 403–408, 2014. View at Publisher · View at Google Scholar
  105. P. Krüger, R. Daneshfar, G. P. Eckert et al., “Metabolism of boswellic acids in vitro and in vivo,” Drug Metabolism and Disposition, vol. 36, no. 6, pp. 1135–1142, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. P. Barrett, A. Flower, and V. Lo, “What's past is prologue: Chinese medicine and the treatment of recurrent urinary tract infections,” Journal of Ethnopharmacology, vol. 167, pp. 86–96, 2015. View at Publisher · View at Google Scholar
  107. J.-P. Liu, M. Han, X.-X. Li et al., “Prospective registration, bias risk and outcome-reporting bias in randomised clinical trials of traditional Chinese medicine: an empirical methodological study,” BMJ Open, vol. 3, no. 7, Article ID e002968, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. Y. N. Yu, J. Liu, L. Zhang, Z. Wang, and D. D. Darrel Duan, “Clinical Zheng-hou pharmacology: the missing link between pharmacogenomics and personalized medicine,” Current Vascular Pharmacology, 2014. View at Publisher · View at Google Scholar